rather the linkage to subsequent events. In addition, in vivo are poorly understood. Here, we show that a previous in vitro and in vivo analyses use the collective mutation in the Rpb2 subunit of Pol II reduces both term "elongation" to cover at least two fundamentally the elongation rate and processivity in vivo. In condistinct aspects of the elongation process. Specifically, trast, none of the putative elongation factors tested there is essentially no information on the relationship affect the elongation rate, although mutations in the between the rate at which elongating Pol II traverses THO complex and in Spt4 significantly reduce procesthe gene and the ability of elongating Pol II to travel the sivity. The drugs 6-azauracil and mycophenolic acid entire length of the gene (processivity). Furthermore, reduce both the elongation rate and processivity, and the factors that govern elongation rate and/or procesthis processivity defect is aggravated by mutations in sivity in vivo are unknown.
Introduction
show that a mutation in the Rpb2 subunit of Pol II and the drugs 6-AU and MPA reduce both the elongation Transcriptional elongation is broadly defined as the rate and processivity. None of the putative elongation process by which Pol II traverses the coding region affactors tested affect the elongation rate, but mutations ter it initiates mRNA synthesis at the promoter. Pol II in the THO complex and in Spt4 significantly reduce elongation factors have been defined by several criprocessivity. TFIIS and CTDK-1, the kinase that phosteria, and they include TFIIS, as well as the Spt4-Spt5, phorylates the C-terminal domain of Pol II at serine 2, Spt6-Iws1, FACT, Paf, THO, Elongator, Set1, and Set2 also affect processivity but only under conditions complexes. Like Pol II itself, these elongation factors where elongation is inhibited by drugs. Our results deassociate with coding regions in vivo in a manner that monstrate that elongation rate and processivity are depends on the level of transcriptional activity ( (Figures 2A and 2B) . We tested cells treated with lower the gene. Using this approach, we examined the functions of many factors and two drugs implicated in tranlevels of 6-AU, with the idea that this might separate the processivity and elongation rate defects. However, scriptional elongation. lower concentrations yielded intermediate phenotypes for both processivity and elongation rate ( Figure 2D ).
Reduced Elongation Rate and Processivity
This indicates that the elongation rate and processivity in a Strain Containing a Mutant Pol II are linked phenomena, consistent with the idea that an We first examined the effect of the rpb2-10 mutation, elongation rate defect will cause a processivity defect. which alters the second-largest Pol II subunit and reduces the Pol II elongation rate in vitro on naked DNA templates (Powell and Reines, 1996). Pol II density was Uracil Depletion Causes Elongation and Processivity Defects, but It Is Not Equivalent to 6-AU Treatment monitored at five positions spanning the GAL1-YLR454 gene ( Figure 1A ) at 1 min intervals following glucose To determine the effects of reduced concentrations of a nucleotide precursor on Pol II elongation, we shifted addition. In the isogenic wild-type strain, the "last wave" of Pol II clears from the 5# to 3# ends of the gene a Ura − strain to medium lacking uracil for 30 min ( Figure  3A ). Under these conditions, Pol II density is redistribas described previously (Strasser et al., Mason and Struhl, 2003) , whereas the rpb2-10 mutant strain uted in a manner similar to that observed upon 6-AU treatment, indicating that uracil depletion is sufficient yields a delayed pattern of Pol II dissociation ( Figures  1B and 1C) . Comparing the time needed for half-dissoto cause a processivity defect. Additionally, like 6-AU, uracil depletion causes a disruption in the pattern of ciation at each position within the coding region indicates that the elongation rate in the rpb2-10 is approxiPol II dissociation following glucose treatment, indicating that it significantly reduces the Pol II elongation rate mately 1 kb/min, compared to the wild-type rate of 2 kb/min ( Figure 1C) . Thus, the rpb2-10 mutation halves ( Figure 3B ). As expected, the processivity defect caused by uracil depletion is rapidly corrected by readdition of the Pol II elongation rate. Additionally, we noticed that key information about the elongation rate could be oburacil to the medium. In contrast, readdition of uracil does not reverse the processivity defect caused by tained by examination of the pattern of Pol II dissociation (in mutant versus isogenic wild-type strains) fol-6-AU ( Figure 3A ), presumably at least partly because 6-AU inhibits IMP dehydrogenase activity and hence lowing a single 4 min glucose treatment ( Figure 1C) , and we exploited this feature of the assay in subselowers GTP pools (Exinger and Lacroute, 1992). These results indicate that limiting the concentration of a sinquent experiments.
Interestingly, the elongation rate defect is accompagle nucleotide precursor is sufficient to cause a significant defect in Pol II processivity and elongation rate nied by reduced processivity ( Figure 1D acerbated in strains lacking TFIIS or either subunit of CTDK1, the kinase that phosphorylates the C-terminal domain of Pol II at serine 2, whereas these strains are TFIIS and CTDK1 Affect Processivity, but Not essentially normal in the absence of 6-AU ( Figure 4C ).
Elongation Rate in the Presence of 6-AU
In the presence of 6-AU, Pol II density is significantly Although strains lacking a given elongation factor do reduced 2 kb from the promoter and virtually absent not show a defect in elongation rate or processivity, at the distal end. Thus, TFIIS and CTDK1 can affect they are often sensitive to 6-AU. This observation suggests that elongation factors may be functionally reprocessivity, although this effect is observed only under conditions where processivity is compromised by the defects on 6-AU plates ( Figure 4C ) is imperfect. For example, whereas growth of cdc73 or rtf1 deletion strains presence of 6-AU.
The severe deficiency of Pol II molecules associated are inhibited by 6-AU, the processivity defect conferred by 6-AU in these strains is comparable to that of wildwith downstream portions of the YLR454 coding region caused by 6-AU in strains lacking TFIIS or CTDK1 comtype. In addition, while ctk1 or ctk2 deletion strains show 6-AU processivity defects similar to ppr2 strains, plicate the use of our standard assay for measuring elongation rate. However, the presence of Pol II molewhich lack TFIIS, loss of TFIIS function causes a more pronounced 6-AU growth defect than loss of CTDK1. cules 2 kb downstream from the promoter ( Figure 4D ) excludes the possibility that Pol II is exclusively stalled This suggests both that these factors have distinct modes of sensitivity to 6-AU and that 6-AU effects cell at the promoter and unable to translocate. To measure elongation rates in TFIIS-or CTDK1-deficient cells growth, and perhaps transcription, at multiple levels. treated with 6AU, we monitored Pol II density over shorter intervals located near the 5# end of the gene Fkh2 Does Not Appear to Affect Processivity at the PMA1 Gene ( Figure 4E ). The 5#-proximal Pol II density in the 6-AUtreated strains lacking TFIIS or CTDK1 decays upon It has been reported that loss of Fkh2, a forkhead transcription factor, causes a dramatic (30-fold) reduction glucose treatment (Figure 4E ), directly demonstrating that Pol II elongation occurs under these conditions. of Pol II density at the 3# end of the PMA1 gene (Morillon et al., 2003). However, using similar primer pairs, Interestingly, the rate of elongation in the TFIIS and CTDK1 mutant strains is similar to, or only marginally our analysis of steady-state Pol II density at PMA1 reveals no defect in either overall Pol II density or procesreduced from, that occurring in the wild-type strain. Thus, TFIIS and CTDK1 are important for processivity sivity upon deletion of Fkh2 ( Figure 4G ). For this reason, Fkh2 was omitted from the panel of factors tested in under conditions where the elongation rate is reduced by 6-AU, but they have little if any affect on the elongaour GAL1-YLR454 assay. We do not understand the basis for the discrepancy between our results and those tion rate itself.
Given the pronounced hypersensitivity to 6-AU caused published previously (Morillon et al., 2003) . by TFIIS deletion, we tested a Ura − version of this strain for the response to uracil depletion. In contrast to the
6-AU Reduces the Association of Initiation Factors in a TFIIS-Deficient Strain case of 6-AU treatment (Figure 4D), deletion of TFIIS did not cause hypersensitivity to uracil depletion (Fig-
Given the pronounced concentration and narrow distribution of Pol II near the promoter in the TFIIS deletion ure 4F). This further suggests that the effects of 6-AU treatment are not exclusively the result of nucleotide strain treated with 6-AU, we examined the association of various transcription factors with the GAL1-YLR454 depletion, and it indicates that TFIIS does not act solely at a step in Pol II translocation that is sensitive to subgene ( Figure 5 ). In the TFIIS-deleted strain, 6-AU treatment does not affect the association of Gal4, but it restrate deprivation.
The correlation between the observed processivity duces association of the core-promoter factors TBP, TFIIB, and TFIIF (Rap74 subunit) by a factor of 2-3. In defects in the presence of 6-AU with respect to growth The processivity defects observed in the absence of 6-AU, while readily detectable, are quantitatively modprocessivity, but not for the elongation rate of Pol II. This suggestion also explains why mutational disrupest. Moreover, the 8 kb YLR454w gene is significantly longer than a typical 1-2 kb yeast gene. Assuming that tion of the THO complex does not exacerbate the processivity defect when the elongation rate is inhibited by Pol II processivity defects are not gene specific, approximately 80%-90% of initiating Pol II elongate through 6-AU.
TFIIS and CTDK1 also affect Pol II processivity witha typical yeast gene in the mutant strains. Thus, it is not surprising that strains lacking Spt4 or THO complex out affecting the elongation rate, but this processivity defect is only observed in the presence of 6-AU. We members grow normally. However, higher eukaryotes contain much longer, intron-rich genes, and it is highly presume that the level of Pol II pausing or at arrest in wild-type cells is sufficiently low such that the minor likely that subtle defects in Pol II processivity would have catastrophic phenotypic effects. In addition, the contribution of TFIIS and CTDK1 to processivity is not observed. In contrast, Pol II pausing and/or arrest inconnection between Pol II elongation rate and processivity suggests that genetic or environmental perturbacreases upon 6-AU treatment, thereby causing a processivity defect that is exacerbated in the absence of tions that subtly reduce elongation rate will also have major biological consequences. These considerations TFIIS or CTDK1. Consistent with this suggestion, TFIIS is required for Pol II elongation through an artificial arunderscore the biological importance of factors such as the THO and Spt4-Spt5 complexes in permitting Pol rest site in vivo, and this arrest site does not function
